Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | ADAM29 |
| Gene Name: | ADAM29 |
| Protein Full Name: | Disintegrin and metalloproteinase domain-containin |
| Alias: | A disintegrin and metalloproteinase domain 29; ADA29; ADAM 29; ADAM metallopeptidase domain 29; Cancer/testis 73; Cancer/testis antigen 73; CT73; Svph1 |
| Mass (Da): | 92740 |
| Number AA: | 820 |
| UniProt ID: | Q9UKF5 |
| Locus ID: | 11086 |
| COSMIC ID: | ADAM29 |
| Gene location on chromosome: | 4q34 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 20241 |
| Percent of cancer specimens with mutations: | 1.81 |
| Commonly recorded point mutations: | T746M (23) |
| Normal role description: | ADAM29 is a single pass type I membrane-bound cell surface protein structurally related to snake venom disintegrins, with a cytoplasmic C-terminal. It is highly expressed in the testes, but only in very low levels or not at all in other tissues, and plays a role in cell-cell and cell-matrix interactions, such as muscle development, neurogenesis, spermatogenesis and fertilization. It appears to be a non-catalytic metalloprotease-protein. It is overexpressed in a number of cancers, such as colorectal cancer. |
| Commentary on involvement of protein in cancer: | Mutations are also found in 1% of lung cancers (2/145). 4% (2/45) of total CNS tumours are mutated - 1 unique glioma and 1 medullablastoma mutation were found. In a study by Oppezzo et al. (2005) in Blood, ADAM29 was proposed as a marker for CLL and as a potential oncoprotein since it is nearly absent in normal B-cells but overexpressed in CLL. Other studies (e.g. one by Ashktorab et al. (2010) in PLoS ONE) have found that ADAM29 is overexpressed in colorectal cancer. In the testes where it is normally highly expressed however, this is probably not the case. |